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Abstract
Background: Herpes zoster (HZ) is caused by reactivation of the varicella-zoster virus (VZV) and mainly affects
individuals aged ≥50 years. The forthcoming European launch of a vaccine against HZ (ZostavaxW) prompts the
need for a better understanding of the epidemiology of HZ in Europe. Therefore the aim of this systematic review
was to summarize the available data on HZ incidence in Europe and to describe age-specific incidence.
Methods: The Medline database of the National Library of Medicine was used to conduct a comprehensive
literature search of population-based studies of HZ incidence published between 1960 and 2010 carried out in the
27 member countries of the European Union, Iceland, Norway and Switzerland. The identified articles were
reviewed and scored according to a reading grid including various quality criteria, and HZ incidence data were
extracted and presented by country.
Results: The search identified 21 studies, and revealed a similar annual HZ incidence throughout Europe, varying by
country from 2.0 to 4.6/1 000 person-years with no clearly observed geographic trend. Despite the fact that age
groups differed from one study to another, age-specific HZ incidence rates seemed to hold steady during the
review period, at around 1/1 000 children <10 years, around 2/1 000 adults aged <40 years, and around 1–4/1 000
adults aged 40–50 years. They then increased rapidly after age 50 years to around 7–8/1 000, up to 10/1 000 after
80 years of age. Our review confirms that in Europe HZ incidence increases with age, and quite drastically after
50 years of age. In all of the 21 studies included in the present review, incidence rates were higher among women
than men, and this difference increased with age. This review also highlights the need to identify standardized
surveillance methods to improve the comparability of data within European Union Member States and to monitor
the impact of VZV immunization on the epidemiology of HZ.
Conclusions: Available data in Europe have shortcomings which make an accurate assessment of HZ incidence
and change over time impossible. However, data are indicative that HZ incidence is comparable, and increases with
age in the same proportion across Europe.
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Background
Varicella-zoster virus (VZV) is a herpes virus that infects
nearly all humans and causes two distinct diseases: vari-
cella, the primary infection which usually occurs in
childhood, and herpes zoster (HZ), a result of reactiva-
tion of VZV which remains latent in the sensory ganglia
following varicella. This reactivation occurs when VZV-
specific cellular-mediated immunity decreases, mainly
due to age-related immunosenescence and immunosup-
pressive conditions.
HZ is characterized by a vesicular skin rash localized
in the sensory region of the affected ganglia, and is often
preceded, or accompanied by acute pain or itching. The
individual lifetime risk of developing HZ is between
23.8% and 30%, or approximately 1 in 4 people [1-5].
However, for individuals aged 85 and over, this risk in-
creases to 1 in 2 people [6]. Indeed, HZ incidence in-
creases markedly after 50 years of age, with two-thirds
of HZ cases occurring in individuals aged 50 years or
over [7]. Anyone who has had varicella is at risk of HZ,
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and in Europe varicella affects over 90% of children be-
fore the age of 15 years [8].
HZ is painful during the acute phase, but pain may
persist for months or even years. Post-herpetic neuralgia,
defined as chronic pain persisting after rash onset, oc-
curs in 20% to 50% of patients, and can lead to several
months of treatment and loss of quality of life [9,10].
After 1 year, almost 10% of patients, mainly older people,
still have persistent pain [11,12].
The forthcoming European launch of a vaccine against
HZ (ZostavaxW) prompts the need for a better under-
standing of the epidemiology of HZ in Europe. There-
fore the aim of this review was to summarize the
available data on HZ incidence in Europe and to de-
scribe age-specific incidence, notably among individuals
aged over 50 years.
Methods
Literature search
The Medline database of the National Library of Medi-
cine was used to conduct a comprehensive literature
search of population-based studies of HZ incidence pub-
lished between 1960 and 2010. Articles had to include
the MeSH term “herpes zoster” or “shingles”, as well as
the keyword “incidence” or “age-specific incidence”.
Only articles reporting on studies carried out in the 27
European Union Member States, Iceland, Norway, or
Switzerland (complete list can be found at end of this
paper) were considered. Publications in Dutch, English,
French, German, Italian or Spanish were considered.
References lists from retrieved publications were also
checked manually for any additional studies or review
articles on the epidemiology of HZ, and if necessary the
authors were contacted to obtain data on age-specific
HZ incidence rates. National surveillance data, the
websites of the National Institutes of Health of the
United Kingdom (UK), sentinel networks and data from
the World Health Organization were also consulted, es-
pecially for countries where no publications were found.
However, no additional data were identified.
Selection criteria
Included articles had to have HZ incidence data avail-
able, a population-based study design and information
on the quality criteria used to score the studies in this
review. Any study that did not contain this information
was excluded.
All studies limited to immunocompromised popula-
tions/populations with primary or acquired immunodefi-
ciency status, patients with hematological malignancies
(acute and chronic leukemia, lymphoma or other malig-
nant neoplasm affecting the bone marrow or lymphatic
system, solid tumors receiving cytotoxic chemotherapy,
hematopoietic stem cell transplantation), persons with
AIDS, patients on immunosuppressive therapy (i.e.,
treatment with agents, such as x-rays, corticosteroids, or
cytotoxic chemicals, etc.) were excluded. A few articles
were also excluded due to duplicate publication, or lack
of study dates.
Quality assessment and scoring of articles
In order to provide a methodological classification of the
studies, a reading grid was created specifically for this
review based on set quality criteria. According to these
criteria, each selected article was scored by two inde-
pendent readers. The reading grid allowed for a total of
30 possible points:
1) Representativeness of the sample of patients (12
points): number of practitioners or specialists,
sampling method description and validation—if any,
geographic distribution, population covered.
2) Incidence calculation (12 points): estimation of the
denominator used to calculate incidence, presence of
confidence intervals, estimation of age- or sex-
specific incidence, size of the study, diagnostic
criteria of HZ.
3) Study design (4 points):
a) Prospective inclusion of patients (considered
high-quality data) suffering from HZ in health
care facilities during a defined study period, either
during an ad-hoc study or through a sentinel
surveillance network.
b) Retrospective identification of HZ cases either
through the review of medical files in a sample of
practitioners, or through the analysis of large
databases (national registries, health insurance
databases, etc.). In the first case, potential issues
could arise from the quality of files and missing
data. Database studies are less time- and cost-
consuming for assessing incidence rates; however
these studies are subject to bias related to the
completeness of the database and inference to the
general population.
4) Discussion of the study limitations and study results
put in perspective with the data from the literature
(2 points).
Papers with a quality score of less than 15 out of the
30 possible points were excluded from the literature re-
view. For the selected articles, pertinent information was
extracted, including study dates, setting, study popula-
tion, sample size, diagnostic criteria used for HZ, overall
HZ incidence with 95% confidence intervals (when avail-
able), and incidence data by age, and by sex (when
available).
The present systematic review is following the PRISMA
guidelines [13].
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Results
The Medline search identified 1 644 articles, of which 1
563 were immediately excluded based on their abstracts.
A review of the reference lists of the 81 remaining arti-
cles identified 23 additional articles, making a total of
104. Of these, 77 were excluded due to the inclusion and
exclusion criteria: four hospital-based studies, six cost-
effectiveness studies (some epidemiological data, but
obtained or derived from several community-based stud-
ies), 34 general reviews, 18 studies in countries not
included in this review, and 15 with no exploitable inci-
dence data or that lacked information on the quality cri-
teria necessary to score the publication.
The 27 remaining articles that corresponded to the in-
clusion criteria were scored using the reading grid. After
the reading grid was applied, six of the 27 studies were
further excluded as they did not meet the threshold for
inclusion (i.e., 15 points) [14-19]. Therefore, 21 articles
were finally included in this review (Figure 1).
The 21 reports of HZ incidence from European coun-
tries included one from Belgium, four from France, two
from Germany, two from Iceland, two from Italy, three
from the Netherlands, two from Spain, one from
Switzerland, and four from the UK (Table 1). No relevant
data were found for the other 21 countries considered in
this review (Austria, Bulgaria, Cyprus, the Czech Republic,
Denmark, Estonia, Finland, Greece, Hungary, Ireland,
Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal,
Romania, Slovenia, Slovakia, Sweden and Norway).
Table 1 shows the main features of the included stud-
ies and HZ incidence by country. Annual HZ incidence
varied by country from 2.0 to 4.57 per 1 000 person-
years (PY). The HZ incidence rates in the studies with a
score inferior to 15 were in the same range (from 3.2
and 4.14 per 1000 person-years) [15,16]. The overall in-
cidence was lower in Iceland, Germany and Switzerland
(around 2/1 000 PY), medium in the UK, the
Netherlands and France (around 3/1 000 PY), and higher
in Belgium, Spain and Italy (around 4/1 000 PY)
(Table 1). However, no geographic trend of overall inci-
dence was clearly observed (Figure 2).
It was estimated that in England and Wales alone
there are approximately 225 000 new cases of HZ each
year [40]. In 2009, the French sentinel network esti-
mated that there were around 350 000 cases of HZ
across all age groups [21]. Another study performed in
France reported around 182 500 incident cases among
immunocompetent people aged 50 years or over [23].
Using the nine most recent studies, which had the
highest quality score for their country and were performed
without age criteria [20,22,26,29,31,35,36,40,41], we esti-
mated an average HZ incidence rate of 3.4 ± 0.2/1 000 for
all age groups combined. If this is applied to the total
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Figure 1 Flow diagram.
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Table 1 Selected details of included studies










000 PY [95% CI] b
1 [20] Belgium 1994-03 Truyers A2 Patients of 51 GPs All Notified by GPs ICPC-code S70 NR 4.57 [4.31-4.79]




454 active GPs (62 809 976
patients)
All
Weekly returns of all
diagnoses
Individual GPs 992 5.52 [5.06-5.98]
3 [22] France 2005-08 Gonzales-Chiappe A2 Patients of ~1200 GPs All Notified by GPs Individual GPs 2375 3.82 [3.64-4.05]
4 [23] France 2005 Mick B1









5 [24] France 1998 Czernichow B1 Patients of 744 GPs All
Postal survey of GPs – cases
seen in previous year
Individual GPs 605 3.20 [3.00-3.40]
6 [25] Germany 2004 Schiffner-Rohe B2 120 399 patients ≥50y
Searches in computerized
records
ICD-10 1176 9.80 [9.20-10.40]
7 [26] Germany 1992-93 Paul A1
Population of Ansbach City
(about 40 000 inhabitants)
All





8 [27] Iceland 1990-95 Helgason A1
Patients of 62 GPs (out of
150 GPs in Iceland)
All Notified by GPs Individual GPs 462 2.00 [1.80-2.20]
9 [28] Iceland 1990-95 Peturssonc A1 Patients of 62 GPs <20y Notified by GPs Individual GPs 118 1.60
10 [29] Italy 2003-05 EmbertiGialloreti B2
Patients of 342 GPs (0.8% of
Italian GPs) (450 000 patients)
≥15y Searches in computerized
records
ICD-9 5675 4.31 [4.11-4.52]
11 [30] Italy 2004 Di Legami A1
Population of Piemonte (26
934 patients)
≥14y Notified by GPs Individual GPs 46 1.74 [1.28-2.32]
12 [31] Netherlands 2001 Opstelten A1
104 GPs (about 390 000
patients)
All Notified by GPs Individual GPs 1080 3.20 [3.00-3.40]
13 [32] Netherlands 1998-01 de Melker B1
Patients of 43 GPs (about 1%
of the Dutch population)
All Notified by GPs Individual GPs NR 3.25
14 [33] Netherlands 1994-99 Opstelten B2





Individual GPs 837 3.40 [2.90-3.90]
15 [34] Spain 2007 Cebrian-Cuenca A1
24 GPs in Valencia community
(about 36 030 patients > 14y)
>14y Notified by GPs Individual GPs 146 4.10 [3.40-4.70]




17 [36] Switzerland 1998-01 Richard A2
Patients of 250 physicians (GPs,
pediatricians, physicians of
internal medicine)




18 [37] UK 2000-06 Gauthier B2
603 GPs Research Database

























Table 1 Selected details of included studies (Continued)
19 [38] UK 1947-72 Hope-Simpson B1
GPs in Cirencester (about 3700
patients)
All All recorded cases NR 321 3.40
20 [39] UK 1994-01 Fleming B2
Up to 91 GPs (RCGP) (About
200 000 patients)
All Weekly returns of all diagnoses Individual GPs 14 532 3.20
21 [40] UK 1991-00 Brisson B2





ICD-9 112 409 3.73
Abbreviations: PY person-years, CI confidence interval, NR not reported, GP general practitioner, ICD-10 International Classification of Diseases, version 10, UK United Kingdom.
a Design:
A. Prospective study: A1: ad hoc health care-based study A2: sentinel practice network-based study.
B. Retrospective study: B1:ad hoc study with review of patients’ medical charts B2: database study.
b For some studies, the confidence interval of incidence is not specified.



















rough estimate of 1.7 ± 0.1 million new HZ cases can be
expected each year in Europe.
Eleven publications from seven countries presented
both overall and specific incidence rates by sex and/or by
age group (See Additional file 1). In spite of the age
groups, which differed from one study to another, age-
specific HZ incidence rates appeared to hold steady during
the review period at around 1/1 000 children <10 years,
around 2/1 000 adults aged < 40 years, around 1–4/1 000
adults aged 40–50 years, and then increased rapidly after
50 years to around 7–8/1 000, up to 10/1 000 at 80 years
of age and older (Figure 3). Figure 3 illustrates that in
many countries in Europe, HZ incidence increases with
age, and quite steeply so after 50 years of age. In all studies
included in this review, incidence rates were consistently
higher among women than men (male/female ratio range:
1.13–1.56), and this difference also increased with age.
Studies performed among immunocompetent people
and among the general population (including both im-
munocompetent and immunocompromised people),
showed that the risk of HZ was higher in the general
population (9.80/1 000 in Germany and 4.31/1 000 in
Italy) than among immunocompetent people (9.50/1 000
(Germany) and 4.07/1 000 (Italy)) [25,29].
Discussion
The present literature review of HZ incidence in Europe
showed similar HZ incidence across the included coun-
tries for which data was available. Overall annual HZ
incidence varied from 2.0–4.6/1 000 PY depending on
the country, which is consistent with previous published
estimates [43], and similar to those published in North
America (1.25–3.7/1 000 PY [44,45]).
Our review confirms that HZ incidence increases
sharply with age, from around 1/1 000 children <10 years
up to 10/1 000 people over 80 years of age. These results
are consistent with recent published estimates by Volpi
et al. [43]. Annual HZ incidence in Europe has been
reported as 0.3–0.74/1 000 children <10 years, 1.6/1 000
adults aged <40 years, 2.5/1 000 adults aged 20–50 years,
7.8/1 000 adults aged 60 years or over, and 10/1 000 in
elderly adults over 80 years of age [43].
As expected, the same increase in incidence rates with
age was observed in the studies included in this review
that reported age-specific incidence (Figure 3). The correl-
ation between age and HZ incidence may be related to a
decreased cellular-mediated immune response to VZV as
result of immunosenescence [44,46]. It has been suggested
that exposure to varicella reduces the risk of VZV reacti-
vation by boosting specific immunity to the virus [38,47].
This hypothesis is supported by some studies which
showed that repeated familial or occupational exposure is
associated with a reduced risk of HZ [48-51], but others
did not confirm this [46,52].
This review showed that incidence rates are systematic-
ally higher among women than men (male/female ratio
around 1.4), and this difference increases with age, which
has also been found in other studies [41,53]. Women over
Figure 2 Overall annual herpes zoster (HZ) incidence rates in Europe (/1 000 person-years). Notes: The confidence interval is presented
when available in the original publication. In case of several publications per country, the publication with the most recent data and that
reported the overall HZ incidence rate is depicted.
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50 years of age seem to be particularly at risk. However, it
is unclear whether the risk of HZ is increased in all
women. Women might simply be more likely to seek
medical advice, thereby causing a higher reporting rate, or
there may be some biological mechanism by which
women are more susceptible to VZV reactivation [54].
Our review excluded studies limited to immunocom-
promised populations, or individuals with primary or ac-
quired immunodeficiency status. Nevertheless, as included
studies were population-based, some of them made a dis-
tinction between the total study population and the im-
munocompetent population [25,29]. This review confirms
that immunocompetent patients are at lower risk of devel-
oping HZ than the general population [25,29]. The control
of VZV reactivation depends on the maintenance of ad-
equate levels of cellular-mediated immunity to VZV,
which explains why cellular-mediated immune deficiency
is a risk factor for developing HZ [54].
In Europe, not all countries have some form of surveil-
lance in place for HZ [55,56] and there is marked hetero-
geneity in the type of HZ surveillance systems that do
exist (national mandatory or sentinel), the type of data
collected (case-based or aggregated) and the reported
case classification (clinical and/or laboratory) [57]. Most
surveillance systems operate using reports of clinical
cases [57].
This review highlights the need to identify standard-
ized surveillance methods in order to improve data
comparability within European Union Member States
and, in the framework of introducing HZ vaccination,
to monitor the impact of immunization on the epi-
demiology of HZ.
Since most of the European studies in this review were
performed and published in the last 10 years, it was
difficult to look at a time trend variation in the risk of
HZ. The only country (the UK) with two incidence rate
estimates, which were about 30 years apart, provided
two close figures: 3.40/1 000 people in 1975 vs. 3.73/1
000 people in 2000 [38,40]. However, this comparison is
delicate since the first study was retrospective [38] and
the second prospective [40].
In the literature, there are conflicting data with regard
to whether age-adjusted HZ incidence is changing over
time [7,58]. Indeed, the literature fails to show evidence
of any change of HZ incidence over time, notably in re-
lation to varicella vaccination. Longitudinal data, includ-
ing a few years of baseline before possible routine use of
the varicella vaccine in children or adolescents, and a
sufficient number of years of data to detect a trend (at
least 3, preferably more) after the implementation of the
vaccine will be needed to assess the impact of varicella
vaccination on HZ incidence [59]. Such data are avail-
able from the US where varicella vaccination has been
used routinely since 1995; however no clear conclusions
were drawn on the impact on HZ incidence. Some au-
thors did not observe any impact of varicella vaccination
on HZ incidence [7,58] and others observed an increase
[60]. Moreover, looking at a potential HZ incidence
trend overtime is challenging and depends on the avail-
ability of baseline data collected using comparable study
methods in populations with comparable health care be-
havior. Comparing results across studies and time pe-
riods must take into account different study methods
and must adjust for changes in the age structure of the
population over time. As the proportion of older people
grows in Europe [61], HZ is likely to become a more im-
portant public health issue in the future. The apparently






























France - Gonzales-Chiappe Germany - Schiffner-Rohe Italy - Gialloreti
Netherlands - de Melker Spain - Garcia-Cenoz UK - Brisson
Figure 3 Herpes zoster incidence by age in Europe. Note: These studies were the most recent with available HZ incidence data by age group
per country.
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due to medical conditions or medication in the popula-
tion, and the effect this may have on HZ, must also be
considered.
This literature review has various limitations. First of
all, this review included studies with different designs:
direct prospective recruitment of patients with HZ in
health care settings during a defined study period, and
retrospective identification through medical files from a
number of practitioners. In general, prospective recruit-
ment methods are considered to be preferable, whereas
retrospective recruitment poses some methodological
problems regarding data quality and missing data. How-
ever, this was taken into account in the reading grid,
which assigned a higher quality score to prospective
studies than retrospective studies.
Moreover, in spite of their potential shortcomings,
some studies based on large databases (UK, Italy, Spain,
Germany) were included in this review. It is true that in
the past the methods used in population-based studies,
such as those used to extrapolate results obtained from
a single database to the entire North American popula-
tion, have been criticized [62]. Indeed, in this case the
fact that the denominator used was the total number of
persons registered in the national health care system and
was presented as exhaustive raised a methodological
problem linked to the calculation of the HZ incidence
rate. This was questionable since no information was
given on the number of persons who were not regis-
tered, compared to the national census. In that case, the
denominator was a surrogate for the true number and
the calculated rate could have been over-estimated. Re-
cently, Yawn et al. showed that administrative data use
alone appears to overestimate the number of HZ cases
[53], and the potential coding error of HZ diagnosis in
administrative data has also been investigated [63].
Conclusions
Available European epidemiological data on HZ have
shortcomings which make accurate assessment of HZ
incidence and change over time impossible. However,
data are indicative that HZ incidence across Europe is
comparable (about 3.4 ± 0.2/1 000 when considering all
age groups) and increases with age, especially after 50 -
years of age. This equates to a total of 1.7 +/− 0.1 mil-
lion new HZ cases each year in Europe.
Complete list of countries
Austria, Belgium, Bulgaria, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, the Netherlands, Norway, Poland,
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
Switzerland, United Kingdom.
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Additional file 1: Incidence rates of herpes zoster (HZ) by age group
and by sex when available (/1 000) [20,22,23,25,29-32,34,35,37,39,40,64].
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HZ: Herpes zoster; PY: Person-years; UK: United Kingdom; VZV: Varicella-zoster
virus.
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